在印度开展跨国肿瘤学临床试验面临的挑战。
Challenges in launching multinational oncology clinical trials in India.
作者信息
Saini Kamal S, Agarwal Gaurav, Jagannathan Ramesh, Metzger-Filho Otto, Saini Monika L, Mistry Khurshid, Ali Raghib, Gupta Sudeep
机构信息
Breast International Group, Department of Medical Oncology, Jules Bordet Institute, Université libre de Bruxelles, Brussels, Belgium.
Department of Endocrine and Breast Surgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
出版信息
South Asian J Cancer. 2013 Jan;2(1):44-9. doi: 10.4103/2278-330X.105896.
In the recent past, there has been an impressive growth in the number of clinical trials launched worldwide, including India. Participation in well-designed oncology clinical trials is of advantage to Indian healthcare system in general, and cancer patients in particular. However, the number of clinical trials being run in India is not commensurate with the cancer burden prevailing in the country. In this article, the authors investigate the reasons for this discrepancy, highlight critical bottlenecks, and propose ways to ameliorate the situation.
最近，包括印度在内，全球开展的临床试验数量有了显著增长。总体而言，参与精心设计的肿瘤学临床试验对印度医疗体系有利，对癌症患者尤其如此。然而，印度正在进行的临床试验数量与该国普遍存在的癌症负担并不相称。在本文中，作者调查了这种差异的原因，突出了关键瓶颈，并提出了改善这种情况的方法。
Zotero 插件